vs
Side-by-side financial comparison of INSEEGO CORP. (INSG) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
INSEEGO CORP. is the larger business by last-quarter revenue ($48.4M vs $28.1M, roughly 1.7× ARS Pharmaceuticals, Inc.). INSEEGO CORP. runs the higher net margin — 1.0% vs -147.1%, a 148.1% gap on every dollar of revenue. On growth, INSEEGO CORP. posted the faster year-over-year revenue change (0.6% vs -67.6%).
Inseego Corp designs, manufactures and delivers advanced 5G and IoT solutions including mobile hotspots, edge computing devices, and cloud-based device management platforms. It primarily serves telecom operators, enterprise clients, and public sector customers across global markets.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
INSG vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $28.1M |
| Net Profit | $469.0K | $-41.3M |
| Gross Margin | 42.2% | — |
| Operating Margin | 2.7% | -147.6% |
| Net Margin | 1.0% | -147.1% |
| Revenue YoY | 0.6% | -67.6% |
| Net Profit YoY | 182.9% | -182.8% |
| EPS (diluted) | $-0.02 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $28.1M | ||
| Q3 25 | $45.9M | $32.5M | ||
| Q2 25 | $40.2M | $15.7M | ||
| Q1 25 | $31.7M | $8.0M | ||
| Q4 24 | $48.1M | $86.6M | ||
| Q3 24 | $54.0M | $2.1M | ||
| Q2 24 | $51.6M | $500.0K | ||
| Q1 24 | $37.5M | $0 |
| Q4 25 | $469.0K | $-41.3M | ||
| Q3 25 | $1.4M | $-51.2M | ||
| Q2 25 | $507.0K | $-44.9M | ||
| Q1 25 | $-1.6M | $-33.9M | ||
| Q4 24 | $-566.0K | $49.9M | ||
| Q3 24 | $9.0M | $-19.1M | ||
| Q2 24 | $624.0K | $-12.5M | ||
| Q1 24 | $-4.5M | $-10.3M |
| Q4 25 | 42.2% | — | ||
| Q3 25 | 41.6% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 47.3% | — | ||
| Q4 24 | 37.3% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 36.4% | — | ||
| Q1 24 | 35.3% | — |
| Q4 25 | 2.7% | -147.6% | ||
| Q3 25 | 4.7% | -163.7% | ||
| Q2 25 | 3.2% | -302.9% | ||
| Q1 25 | -1.3% | -466.3% | ||
| Q4 24 | 3.7% | 54.5% | ||
| Q3 24 | 1.9% | -1051.6% | ||
| Q2 24 | 3.6% | -3068.0% | ||
| Q1 24 | -7.9% | — |
| Q4 25 | 1.0% | -147.1% | ||
| Q3 25 | 3.1% | -157.4% | ||
| Q2 25 | 1.3% | -285.6% | ||
| Q1 25 | -5.0% | -425.7% | ||
| Q4 24 | -1.2% | 57.7% | ||
| Q3 24 | 16.6% | -925.0% | ||
| Q2 24 | 1.2% | -2503.2% | ||
| Q1 24 | -11.9% | — |
| Q4 25 | $-0.02 | $-0.41 | ||
| Q3 25 | $0.03 | $-0.52 | ||
| Q2 25 | $-0.03 | $-0.46 | ||
| Q1 25 | $-0.16 | $-0.35 | ||
| Q4 24 | $0.62 | $0.52 | ||
| Q3 24 | $-0.06 | $-0.20 | ||
| Q2 24 | $-0.02 | $-0.13 | ||
| Q1 24 | $-0.44 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.9M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $-4.0M | $114.3M |
| Total Assets | $93.8M | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.9M | $245.0M | ||
| Q3 25 | $14.6M | $288.2M | ||
| Q2 25 | $13.2M | $240.1M | ||
| Q1 25 | $35.1M | $275.7M | ||
| Q4 24 | $39.6M | $314.0M | ||
| Q3 24 | $12.0M | $204.6M | ||
| Q2 24 | $49.0M | $218.7M | ||
| Q1 24 | $12.3M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-4.0M | $114.3M | ||
| Q3 25 | $-7.7M | $147.7M | ||
| Q2 25 | $-10.5M | $192.3M | ||
| Q1 25 | $-13.0M | $229.0M | ||
| Q4 24 | $-12.9M | $256.8M | ||
| Q3 24 | $-85.1M | $201.0M | ||
| Q2 24 | $-101.8M | $215.2M | ||
| Q1 24 | $-105.6M | $223.9M |
| Q4 25 | $93.8M | $327.7M | ||
| Q3 25 | $85.8M | $372.8M | ||
| Q2 25 | $83.1M | $313.5M | ||
| Q1 25 | $93.0M | $327.3M | ||
| Q4 24 | $100.0M | $351.2M | ||
| Q3 24 | $113.4M | $217.6M | ||
| Q2 24 | $149.6M | $222.0M | ||
| Q1 24 | $122.1M | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.0M | $-43.5M |
| Free Cash FlowOCF − Capex | $11.6M | — |
| FCF MarginFCF / Revenue | 24.0% | — |
| Capex IntensityCapex / Revenue | 0.7% | 0.0% |
| Cash ConversionOCF / Net Profit | 25.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.0M | $-43.5M | ||
| Q3 25 | $3.2M | $-47.0M | ||
| Q2 25 | $-4.5M | $-39.6M | ||
| Q1 25 | $-3.5M | $-40.7M | ||
| Q4 24 | $-14.2M | $42.0M | ||
| Q3 24 | $14.8M | $-14.5M | ||
| Q2 24 | $27.6M | $-7.3M | ||
| Q1 24 | $5.2M | $-6.7M |
| Q4 25 | $11.6M | — | ||
| Q3 25 | $3.1M | $-47.2M | ||
| Q2 25 | $-4.7M | $-39.6M | ||
| Q1 25 | $-3.5M | $-40.8M | ||
| Q4 24 | $-14.3M | $41.7M | ||
| Q3 24 | $14.8M | $-14.6M | ||
| Q2 24 | $27.6M | $-7.3M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | 24.0% | — | ||
| Q3 25 | 6.7% | -145.4% | ||
| Q2 25 | -11.6% | -252.2% | ||
| Q1 25 | -11.0% | -512.1% | ||
| Q4 24 | -29.7% | 48.2% | ||
| Q3 24 | 27.4% | -706.3% | ||
| Q2 24 | 53.5% | -1463.4% | ||
| Q1 24 | — | — |
| Q4 25 | 0.7% | 0.0% | ||
| Q3 25 | 0.2% | 0.6% | ||
| Q2 25 | 0.5% | 0.3% | ||
| Q1 25 | 0.1% | 1.1% | ||
| Q4 24 | 0.1% | 0.3% | ||
| Q3 24 | 0.0% | 6.8% | ||
| Q2 24 | 0.0% | 7.6% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 25.50× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | -8.81× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 44.31× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INSG
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
